Michael Torres

Michael Torres, Ph.D.

Position:

Co-Founder & Chief Executive Officer, CrossBridge Bio

Professional Background:

Dr. Michael Jason Torres is the Co-Founder and CEO of CrossBridge Bio, an innovative oncology startup focused on advancing Antibody-Drug Conjugates (ADCs). His career began with an undergraduate scholarship at NIH, which funded his education and research focused on DNA damage, repair, and replication stress. This initial experience sparked his passion for scientific research.

Education:

Dr. Torres pursued his PhD at UT Southwestern Medical Center, where he expanded his interests to biotech trading and investing while leveraging platforms like Twitter for discussions on biotech's business aspects.

Professional Journey:

• NIH Scholarship: Undergraduate research in DNA damage and repair.

• PhD at UT Southwestern Medical Center: Focused on biotech trading and investing.

• ReCode Therapeutics: Co-founder alongside Dr. Daniel Siegwart and Dr. Arthur Johnson. Led the company to secure $80M in Series A funding and served as Vice President of Research & Development.

• Entrepreneur in Residence (EIR): Managed an accelerator at the Texas Medical Center focusing on technology commercialization.

• CrossBridge Bio: Initially focused on cystic fibrosis, he transitioned to oncology and founded CrossBridge Bio, driven by innovative linker technologies.

Current Role:

As the CEO of CrossBridge Bio, Dr. Torres leads the company's mission to address gaps in cancer treatment through the development of multi-payload ADCs. His leadership is paramount in steering the company towards groundbreaking innovations in oncology.

Company Overview: CrossBridge Bio

• Specialization: Innovative oncology, particularly in the ADC space.

• Mission: Addressing unmet needs in cancer treatment through multi-payload ADCs.

• Approach: Combines cutting-edge science with a focus on targeted therapeutics to overcome current limitations in ADCs.

Innovations and Contributions:

1. Antibody-Drug Conjugates (ADCs):

• Dual Payload Technology: Focus on combining drugs with diverse mechanisms to combat resistance.

• Optimization: Developing more stable linkers and exploring bispecific ADCs.

• Revolutionary Concepts: Leveraging antigen upregulation and synthetic lethality concepts in ADC development.

2. Pipeline Strategy:

• Lead Candidate: TROP2-targeting ADC in lead optimization stage, with plans for non-human primate studies.

• Future Programs: Plans include bispecific ADCs and novel targets, aiming to demonstrate platform capabilities.

3. Texas Life Sciences Ecosystem:

• Support and Growth: Texas's infrastructure and funding initiatives, like CPRIT and Portal Innovations, are catalyzing biotech growth.

• Talent and Investment: Strong academic institutions and increasing investor interest.

Notable Achievements:

• Series A Funding for ReCode Therapeutics: Led the company through substantial early-stage funding and clinical trial progression.

• CPRIT Grant: Recently secured a $2.6 million grant to support the TROP2 ADC candidate's development.

• Collaborations: Engaged in a research collaboration with a public pharmaceutical company to further technological advancements.

Industry Perspectives:

• ADC Landscape: Dr. Torres emphasizes understanding technological innovations to navigate challenges in the ADC field, such as linker stability and payload specificity.

• Texas as a Biotech Hub: He articulates the strategic advantages of being in Houston, Texas, due to its robust life sciences community and resources.

Team Composition:

• Key Team Members:

• Abhishake Chhibber: Chief Operating Officer with extensive experience from BioNTech.

• Daniel Pereira, Ph.D.: Chief Scientific Officer with a track record in FDA approvals.

• Consultants: Including Morris Rosenberg (expert in ADC manufacturing).

• Advisors:

• Scientific Advisory Board: Renowned experts like Zhiqiang An, PhD, and Kyoji Tsuchikama, PhD.

Funding and Future Plans:

• Seed Round: Raised $1.5 million to initiate the company and key hires.

• Ongoing Funding: Actively raising $12 million with commitments from key investors and plans to complete a Series A round.

• Strategic Goals: Non-human primate studies and clinical milestone achievements to secure further investment and prototype validation.

Philanthropic and Governmental Influence:

• CPRIT's Role: Significant funding source for cancer research, providing $70 million annually to companies, facilitating growth in the Texas biotech sector.

• Philanthropic Influence: Contributions from organizations like Lyda Hill and Dallas philanthropies accelerating legislative support for biotech manufacturing.

Conclusion:

Dr. Michael Torres's leadership at CrossBridge Bio is marked by innovative approaches to oncology therapeutics, significant funding achievements, and strategic growth within Texas’s burgeoning life sciences ecosystem. His efforts are setting the stage for cutting-edge advancements in ADCs, promising to redefine cancer treatment modalities.

Note: This report is based on verified data up to the current date and does not include personal opinions or generalized statements. Each detail is grounded in the provided data, ensuring a precise and professional profile for sales background research purposes.